GCM
GILD icon

Gladius Capital Management’s Gilead Sciences GILD Stock Holding History

Gladius Capital Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-350,000
Closed -$21.6M – 386
2022
Q3 		$21.6M Hold
350,000
– – 0.95% 19
2022
Q2 		$21.6M Buy
+350,000
New +$21.7M 1.12% 26

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gladius Capital Management's GILD Position: Q1 2024 in Review

Gladius Capital Management sold out of Gilead Sciences (GILD) in Q1 2024, closing a stake of 418 shares — an estimated $33.9K sold.

Gladius Capital Management first reported a position in GILD in Q4 2018 and held it in 10 quarters. The position peaked at $18.3M in Q1 2022. 1,722 funds tracked by Wall St. Rank hold GILD as of Q1 2024.

  • Gladius Capital Management reported no remaining Gilead Sciences position as of Q1 2024 after selling out during the quarter.
  • Gladius Capital Management sold 418 Gilead Sciences shares in Q1 2024, an estimated $33.9K.
  • Gladius Capital Management first reported a position in Gilead Sciences in Q4 2018 and held it in 10 quarters.
  • Gladius Capital Management's Gilead Sciences position peaked at $18.3M in Q1 2022.
  • 1,722 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2024.

Based on Gladius Capital Management's 13F filing for Q1 2024, filed 14 May 2024.